A Content Analysis of Web Pages on “Weight-Loss Injections”

Asuman Okur

doi:10.70058/cjm.1852434

A Content Analysis of Web Pages on “Weight-Loss Injections”

Abstract

Objective: In recent years, injectable glucagon-like peptide-1 (GLP-1) receptor agonists have gained widespread attention due to their effectiveness in obesity management. However, these agents are frequently presented in media using simplified and misleading terminology such as “weight loss injections,” which may create unrealistic expectations and encourage inappropriate or off-label use. This study aimed to evaluate the content and characteristics of online information about weight-loss injections from a public health and ethical health communication perspective.

Methods: This descriptive study employed qualitative content analysis of publicly accessible Turkish-language web pages. Data were collected between October and November 2025 using a Google search. Web pages published by private hospitals, private clinics, blogs, and news websites that provided informational or promotional content were included. Textual content was analyzed for the presence of medical indications, contraindications, complications, and side effects, prescription warnings, scientific references, emphasis on medical supervision, and recommendations for lifestyle modification. Visual content was assessed in terms of gender representation, depicted body type, and the use of symbolic elements such as pen needles. Quantitative findings were summarized descriptively, and inductive qualitative analysis was conducted to identify prominent themes.

Results: A total of 44 web pages were analyzed. Scientific references and warnings that the product should be obtained by prescription were frequently absent. Although most pages emphasized medical supervision and lifestyle changes, information on indications and contraindications was often incomplete. Visual analysis showed a predominance of female and normal-weight body representations, potentially reinforcing narrow body ideals. Qualitative analysis identified themes including medical legitimacy, social media influence, psychological risks, and concerns regarding unauthorized access.

Conclusion: Online content related to “weight loss injections” demonstrates significant scientific, ethical, and communicative shortcomings. Improving the quality of digital health communication and reframing these agents as medical treatments rather than cosmetic solutions is

Keywords

Supporting Institution

This study did not receive any financial support or funding from any source.

Ethical Statement

This study analyzed only publicly accessible internet content and did not involve any personal data or human participants. Therefore, ethical committee approval was not required.

References

Phelps NH, Singleton RK, Zhou B, Heap RA, Mishra A, Bennett JE, et al. Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024;403(10431):1027-50.
Popoviciu MS, Păduraru L, Yahya G, Metwally K, Cavalu S. Emerging role of GLP-1 agonists in obesity: a comprehensive review of randomised controlled trials. Int J Mol Sci. 2023;24(13):10449. doi:10.3390/ijms241310449.
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989-1002. doi:10.1056/NEJMoa2032183.
Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28:2083-91. doi:10.1038/s41591-022-02026-4.
Mailhac A, Pedersen L, Pottegård A, Søndergaard J, Mogensen T, Sørensen HT, et al. Semaglutide (Ozempic) use in Denmark 2018 through 2023: user trends and off-label prescribing for weight loss. Clin Epidemiol. 2024;16:307-18. doi:10.2147/CLEP.S456170.
Butuca A, Dobrea CM, Arseniu AM, Frum A, Chis AA, Rus LL, et al. An assessment of semaglutide safety based on real world data: from popularity to spontaneous reporting in EudraVigilance database. Biomedicines. 2024;12(5):1124. doi:10.3390/biomedicines12051124.
Kamiński M, Miętkiewska-Dolecka M, Kręgielska-Narożna M, Bogdański P. Popularity of surgical and pharmacological obesity treatment methods searched by Google users: the retrospective analysis of Google Trends statistics in 2004-2022. Obes Surg. 2024;34:882-91. doi:10.1007/s11695-023-06971-y.
Chiappini S, Papanti Pelletier GD, Vickers-Smith R, Corkery JM, Guirguis A, Martinotti G, et al. Exploring the nexus of binge eating disorder (BED), New Psychoactive Substances (NPS), and misuse of pharmaceuticals: charting a path forward. Expert Opin Pharmacother. 2023;24(18):1915-8. doi:10.1080/14656566.2023.2271389.

Batu Z, Batu M, Tos O. Identification of weakness as an ideal myth based on popular culture: a semiotic analysis of weight loss products. Iğdır Üniversitesi Sosyal Bilimler Dergisi. 2022;30:41-58. doi:10.54600/igdirsosbilder.982395.
Karasaç Gezen A. Healthy life as ideology and expert discourses in television programs: the program “a new day with Çağla”. İletişim Kuram ve Araştırma Dergisi. 2024;67:1-15. doi:10.47998/ikad.1343520.
Çimen Ü, Çimen Ö. From health communication to fitness communication: Zygmunt Bauman’s approach to the loss of meaning of health in the postmodern era. Kronotop İletişim Dergisi. 2024;1(2):169-89.
Bayramoğlu A, Demir P, Buzkurt S. Attitudes of university students for diet pills. Turkish Journal of Science and Health. 2021;2(2):48-53. doi:10.51972/tfsd.837158.
Demir S, Karaağaoğlu N. Obesity, body image and weight loss practices of three generation women. Journal of Nutrition and Dietetics. 2013;41(1):18-26. Available from: https://beslenmevediyetdergisi.org/index.php/bdd/article/view/198.
Han SH, Safeek R, Ockerman K, Trieu N, Mars P, Klenke A, et al. Public interest in the off-label use of glucagonlike peptide 1 agonists (Ozempic) for cosmetic weight loss: a Google Trends analysis. Aesthet Surg J. 2023;44(1):60-7. doi:10.1093/asj/sjad211.
Chiappini S, Vickers-Smith R, Harris D, Papanti Pelletier GD, Corkery JM, Guirguis A, et al. Is there a risk for semaglutide misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) pharmacovigilance dataset. Pharmaceuticals. 2023;16(7):994. doi:10.3390/ph16070994.
Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414-25. doi:10.1001/jama.2021.3224.
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-16. doi:10.1056/NEJMoa2206038
Arillotta D, Floresta G, Guirguis A, Corkery JM, Catalani V, Martinotti G, et al. GLP-1 receptor agonists and related mental health issues: insights from a range of social media platforms using a mixed-methods approach. Brain Sci. 2023;13(11):1503. doi:10.3390/brainsci13111503.
Reardon RE. Implications of Ozempic: a semaglutide with peptide (GLP)-1 receptor agonists misused for cosmetic weight loss. Undergraduate Research Journal for the Human Sciences. 2025;18:2025. Available from: https://newprairiepress.org/urjhs/vol18/iss2025/5/.
Sezgin D, Yıldırım İE. Obesity in the media in Turkey from the perspective of those living with obesity. International Journal of Social Sciences. 2022;6(2):19-35. doi:10.30830/tobider.sayi.11.2.

Details

Primary Language

English

Subjects

Clinical Sciences (Other)

Journal Section

Research Article

Authors

Asuman Okur ^*
0000-0003-0837-6988
Türkiye

Early Pub Date

March 28, 2026

Publication Date

March 28, 2026

Submission Date

December 30, 2025

Acceptance Date

March 22, 2026

Published in Issue

Year 2026 Volume: 3 Number: 2

DOI

https://doi.org/10.70058/cjm.1852434

IZ

https://izlik.org/JA39RZ58PB

Cite

RIS / Bibtex

APA

Okur, A. (2026). A Content Analysis of Web Pages on “Weight-Loss Injections”. Cerasus Journal of Medicine, 3(2), 114-123. https://doi.org/10.70058/cjm.1852434

AMA

1.Okur A. A Content Analysis of Web Pages on “Weight-Loss Injections.” Cerasus J Med. 2026;3(2):114-123. doi:10.70058/cjm.1852434

Chicago

Okur, Asuman. 2026. “A Content Analysis of Web Pages on ‘Weight-Loss Injections’”. Cerasus Journal of Medicine 3 (2): 114-23. https://doi.org/10.70058/cjm.1852434.

EndNote

Okur A (May 1, 2026) A Content Analysis of Web Pages on “Weight-Loss Injections”. Cerasus Journal of Medicine 3 2 114–123.

IEEE

[1]A. Okur, “A Content Analysis of Web Pages on ‘Weight-Loss Injections’”, Cerasus J Med, vol. 3, no. 2, pp. 114–123, May 2026, doi: 10.70058/cjm.1852434.

ISNAD

Okur, Asuman. “A Content Analysis of Web Pages on ‘Weight-Loss Injections’”. Cerasus Journal of Medicine 3/2 (May 1, 2026): 114-123. https://doi.org/10.70058/cjm.1852434.

JAMA

1.Okur A. A Content Analysis of Web Pages on “Weight-Loss Injections”. Cerasus J Med. 2026;3:114–123.

MLA

Okur, Asuman. “A Content Analysis of Web Pages on ‘Weight-Loss Injections’”. Cerasus Journal of Medicine, vol. 3, no. 2, May 2026, pp. 114-23, doi:10.70058/cjm.1852434.

Vancouver

1.Asuman Okur. A Content Analysis of Web Pages on “Weight-Loss Injections”. Cerasus J Med. 2026 May 1;3(2):114-23. doi:10.70058/cjm.1852434